Nyheter/rapporter

Senaste pressmeddelanden och rapporter för bevakat bolag.

Datum Källa Rubrik Typ Alternativ
2022-07-27 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Vivesto AB Pressreleaser Visa Stäng
2022-07-04 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Vivesto AB Pressreleaser Visa Stäng
2022-07-01 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Vivesto AB Pressreleaser Visa Stäng
2022-06-30 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Vivesto AB Pressreleaser Visa Stäng
2022-04-26 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Vivesto AB Pressreleaser Visa Stäng
2022-04-20 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Vivesto AB Pressreleaser Visa Stäng
2022-04-06 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Vivesto AB Pressreleaser Visa Stäng
2022-04-01 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Vivesto AB Pressreleaser Visa Stäng
2021-10-08 Edison Investment Research Limited Oasmia Pharmaceutical (OASM): Focused on pillars of growth Pressreleaser Visa Stäng
Pressreleaser | 8 Oct 2021 | Vivesto

Oasmia Pharmaceutical (OASM): Focused on pillars of growth

Edison Investment Research Limited
Oasmia Pharmaceutical (OASM): Focused on pillars of growth

08-Oct-2021 / 10:18 GMT/BST


 

London, UK, 8 October 2021

 

Oasmia Pharmaceutical (OASM): Focused on pillars of growth

Oasmia Pharmaceutical has made steady progress in its ongoing transition into an R&D-driven, speciality pharma company with commercially available assets. The in-licensing of Cantrixil from Kazia Therapeutics in March is the first of its ’string of pearls’ strategy to bolster the pipeline. Oasmia now has three oncology assets under its belt. Partner Elevar Therapeutics now expects to initiate the additional trials required by the FDA to enable the NDA submission for Apealea (Cremophor-free paclitaxel) in ovarian cancer in 2022 (we forecast US launch in 2025). Over the next 12 months, we expect divestment of the animal health business, further in-licensing deals and optimisation of its platform technologies, which represent value drivers beyond Apealea. Our revised valuation is SEK2.89bn or SEK6.45/share.

 

Our updated valuation is SEK2.89bn or SEK6.45/share versus SEK2.84bn or SEK6.34/share previously. Our valuation includes net cash of SEK176.3m plus rNPVs for Apealea (ovarian cancer), Cantrixil (ovarian cancer), docetaxel micellar (prostate cancer) and an indicative value for the animal health business. We do not include the XR-17 platform or other cancer indications in our valuation. 

Click here to view the full report or here to sign up to receive research as it is published.

 

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached – across institutions, family offices, wealth managers and retail investors – Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority .

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Dr Susie Jana +44 (0)20 3077 5700 healthcare@edisongroup.com

Dr John Priestner +44 (0)20 3077 5700 healthcare@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on: 

LinkedIn        www.linkedin.com/company/edison-group-/

Twitter           www.twitter.com/Edison_Inv_Res

YouTube       www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement – EQS News Service

1239463  08-Oct-2021 

fncls.ssp?fn=show_t_gif&application_id=1239463&application_name=news&site_id=millistream

2021-09-02 Oasmia Pharmaceutical Oasmia Pharmaceutical: Analysguiden: Fortsatta framsteg i projektportföljen Pressreleaser Visa Stäng
2021-04-22 Oasmia Pharmaceutical Oasmia Pharmaceutical: Analysguiden: Positiva data för Cantrixil Pressreleaser Visa Stäng
2021-03-15 Oasmia Pharmaceutical Oasmia Pharmaceutical: Analysguiden, intervju med Oasmia: "Vi har ett av sektorns bästa team" Pressreleaser Visa Stäng
2021-02-19 Oasmia Pharmaceutical Oasmia Pharmaceutical: Analysguiden: Interview with CEO Pressreleaser Visa Stäng
2020-12-14 Oasmia Pharmaceutical Oasmia Pharmaceutical: Analysguiden: Intervju efter det gångna kvartalet Pressreleaser Visa Stäng
2020-11-30 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Oasmia Pharmaceutical AB Pressreleaser Visa Stäng
2020-11-26 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Oasmia Pharmaceutical AB Pressreleaser Visa Stäng
2020-10-15 Oasmia Pharmaceutical Oasmia Pharmaceutical: Analysguiden: Stora triggers i närtid Pressreleaser Visa Stäng
2020-07-30 Oasmia Pharmaceutical Oasmia Pharmaceutical: Analysguiden: Intervju med Oasmia "Positionerade för att nå våra högt uppsatta mål" Pressreleaser Visa Stäng
2020-06-17 Oasmia Pharmaceutical Oasmia Pharmaceutical: Analysguiden: Europeisk partner för Apealea nästa trigger Pressreleaser Visa Stäng
2020-01-09 Oasmia Pharmaceutical Oasmia to present at Biotech Showcase in San Francisco Pressreleaser Visa Stäng
2020-01-09 Oasmia Pharmaceutical Oasmia håller presentation på Biotech Showcase i San Francisco Pressreleaser Visa Stäng
2020-01-02 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Oasmia Pharmaceutical AB Pressreleaser Visa Stäng
2019-12-30 Oasmia Pharmaceutical Nytt antal aktier och röster i Oasmia Pharmaceutical AB (publ) Pressreleaser Visa Stäng
2019-12-30 Oasmia Pharmaceutical New number of shares and votes in Oasmia Pharmaceutical AB (publ) Pressreleaser Visa Stäng
2019-12-30 Oasmia Pharmaceutical Oasmia Pharmaceutical AB (publ) Interim report for the period May 1 – October 31, 2019 Rapporter Visa Stäng
2019-12-30 Oasmia Pharmaceutical Oasmia Pharmaceutical AB (publ) Delårsrapport för perioden 1 maj – 31 oktober 2019 Rapporter Visa Stäng
2019-12-20 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Oasmia Pharmaceutical AB Pressreleaser Visa Stäng
2019-12-09 Oasmia Pharmaceutical Final result of the rights issue in Oasmia Pressreleaser Visa Stäng
2019-12-09 Oasmia Pharmaceutical Slutligt utfall i Oasmias företrädesemission Pressreleaser Visa Stäng
2019-12-06 Oasmia Pharmaceutical Oasmia’s rights issue has been oversubscribed Pressreleaser Visa Stäng
2019-12-06 Oasmia Pharmaceutical Oasmias företrädesemission övertecknad Pressreleaser Visa Stäng
2019-11-27 Oasmia Pharmaceutical Rättelse: VD i Oasmia köper teckningsrätter i pågående nyemission Pressreleaser Visa Stäng
2019-11-27 Oasmia Pharmaceutical Correction: The CEO of Oasmia buys subscription rights in the ongoing rights issue Pressreleaser Visa Stäng
2019-11-27 Oasmia Pharmaceutical VD och styrelseordförande i Oasmia köper teckningsrätter i pågående nyemission Pressreleaser Visa Stäng
2019-11-27 Oasmia Pharmaceutical The CEO and Chairman of the Board of Oasmia buys subscription rights in the ongoing rights issue Pressreleaser Visa Stäng
2019-11-19 Oasmia Pharmaceutical Oasmia publishes prospectus in connection with the rights issue of approximately SEK 399 million and updated information included in the prospectus Pressreleaser Visa Stäng
2019-11-19 Oasmia Pharmaceutical Oasmia offentliggör prospekt i samband med företrädesemission om cirka 399 MSEK samt uppdaterad information som återfinns i prospektet Pressreleaser Visa Stäng
2019-11-18 Oasmia Pharmaceutical Oasmia invites to investor meetings in connection to the rights issue Pressreleaser Visa Stäng
2019-11-18 Oasmia Pharmaceutical Oasmia bjuder in till investerarträffar i samband med företrädesemissionen Pressreleaser Visa Stäng
2019-11-11 Oasmia Pharmaceutical Oasmia beslutar om en företrädesemission om cirka 399 MSEK Pressreleaser Visa Stäng
2019-11-11 Oasmia Pharmaceutical Oasmia resolves on a rights issue of approximately SEK 399 million Pressreleaser Visa Stäng

Kommande händelser

25 Aug 2022 | Kvartalsrapport 2022-Q2
17 Nov 2022 | Kvartalsrapport 2022-Q3
23 Feb 2023 | Bokslutskommuniké 2022